Document Classification

Section Type: RESULTS

Text: In NSTE-ACS patients, the primary endpoint was reduced with ticagrelor vs. clopidogrel [10. 0 vs. 12. 3 % ; hazard ratio (HR) 0. 83 ; 95 % confidence interval (CI) = 0. 74-0. 93], as was myocardial infarction (6. 6 vs. 7. 7 % ; HR 0. 86 ; 95 % CI = 0. 74-0. 99), cardiovascular death (3. 7 vs. 4. 9 % ; HR 0. 77 ; 95 % CI = 0. 64-0. 93), and all-cause death (4. 3 vs. 5. 8 % ; HR 0. 76 ; 95 % CI = 0. 64-0. 90).